CUSIP: 35655L107
Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / SPONSORED ADS
-
Total 13F shares
-
37,990,866
-
Share change
-
+2,099,293
-
Total reported value
-
$33,216,000
-
Price per share
-
$0.87
-
Number of holders
-
16
-
Value change
-
+$1,800,193
-
Number of buys
-
6
-
Number of sells
-
7
Quarterly Holders Quick Answers
What is CUSIP 35655L107?
CUSIP 35655L107 identifies FRLN - FREELINE THERAPEUTICS HLDGS - SPONSORED ADS in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2022
-
Previous quarter:
Q1 2022
Recent filing periods for CUSIP 35655L107:
Institutional Holders of FREELINE THERAPEUTICS HLDGS - SPONSORED ADS (FRLN) as of Q2 2022
As of 30 Jun 2022,
FREELINE THERAPEUTICS HLDGS - SPONSORED ADS (FRLN) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
37,990,866 shares.
The largest 10 holders included
Syncona Portfolio Ltd, EVENTIDE ASSET MANAGEMENT, LLC, CHI Advisors LLC, TFG Asset Management GP Ltd, UBS Group AG, RENAISSANCE TECHNOLOGIES LLC, MORGAN STANLEY, HARBOR CAPITAL ADVISORS, INC., TWO SIGMA INVESTMENTS, LP, and FEDERATED HERMES, INC..
This page lists
16
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.